Tumour subgroups | HRT use | Number of cases | HR crude | p | HR adjusted | p |
---|---|---|---|---|---|---|
CRC | No | 236 | 1.00 | 1.00 | ||
ERT | 24 | 0.89(0.59-1.35) | 0.583 | 0.94(0.62-1.44) | 0.788 | |
CHRT | 41 | 0.74(0.53-1.03) | 0.076 | 0.94(0.67-1.31) | 0.701 | |
T stage 1 & 2 | No | 54 | 1.00 | 1.00 | ||
ERT | 3 | 0.53(0.17-1.70) | 0.284 | 0.56(0.17-1.80) | 0.560 | |
CHRT | 3 | 0.24(0.09-0.77) | 0.016 | 0.30(0.09-0.96) | 0.043 | |
T stage 3 & 4 | No | 156 | 1.00 | 1.00 | ||
ERT | 17 | 0.93(0.56-1.52) | 0.761 | 1.01(0.61-1.67) | 0.966 | |
CHRT | 32 | 0.87(0.59-1.27) | 0.471 | 1.14(0.77-1.68) | 0.511 | |
N0 | No | 119 | 1.00 | 1.00 | ||
ERT | 14 | 1.03(0.59-1.79) | 0.912 | 1.15(0.66-2.01) | 0.615 | |
CHRT | 22 | 0.79(0.50-1.24) | 0.302 | 1.05(0.66-1.67) | 0.838 | |
N1 & N2 | No | 79 | 1.00 | 1.00 | ||
ERT | 7 | 0.75(0.35-1.63) | 0.471 | 0.78(0.36-1.68) | 0.522 | |
CHRT | 15 | 0.81(0.47-1.40) | 0.449 | 0.95(0.54-1.67) | 0.860 | |
M0 | No | 181 | 1.00 | 1.00 | ||
ERT | 20 | 0.96(0.61-1.52) | 0.863 | 1.04(0.66-1.66) | 0.861 | |
CHRT | 34 | 0.80(0.55-1.15) | 0.232 | 1.03(0.71-1.49) | 0.893 | |
M1 | No | 45 | 1.00 | 1.00 | ||
ERT | 4 | 0.78(028–2.16) | 0.632 | 0.77(0.28-2.16) | 0.625 | |
CHRT | 7 | 0.66(0.30-1.47) | 0.311 | 0.80(0.36-1.80) | 0.589 |